List view / Grid view
3 October 2016 | By Niamh Louise Marriott, Digital Content Producer
MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb trial for Crohn’s disease (a chronic inflammatory disease of the intestines) and is...
3 October 2016 | By Niamh Louise Marriott, Digital Content Producer
People with the autoimmune disease, psoriasis, also report that they face discrimination, humiliation, and mental illness...
30 September 2016 | By Niamh Louise Marriott, Digital Content Producer
For the investigational, pan-genotypic regimen of glecaprevir /pibrentasvir (ABT-530) (G/P) for the treatment of patients with chronic hepatitis C...
30 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Granulox increases levels of oxygen at the wound bed, speeding up the rate of healing in wounds, venous leg ulcers, by 75% compared to standard care...
30 September 2016 | By Niamh Louise Marriott, Digital Content Producer
6 years after receiving a single treatment with gene therapy, patients with the debilitating genetic disease LPLD had 50% fewer episodes of pancreatitis...
30 September 2016 | By Cherwell Laboratories
Overall demand up by 15% with on-site calibrations showing most significant rise...
29 September 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE are recommending it as an option to treat adults with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy...
29 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Under the terms of the collaboration, Boehringer Ingelheim receives the right to acquire ViraTherapeutics after conclusion of Phase I clinical development...
28 September 2016 | By European Pharmaceutical Review
European Pharmaceutical Review invites you to participate in this brief survey on Pharmaceutical Water Testing for the chance to win one of 40+ Amazon Gift Cards ranging from €5 to €100!
28 September 2016 | By Syrris
Syrris, a world leader in chemistry product innovation, is launching the Orb Pilot jacketed reactor this fall...
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Approximately 10% of the general population suffer from onychomycosis and a majority of those afflicted go untreated. The prescription market is growing...
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Bristol-Myers' Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression and NKTR-214 is an immuno-stimulatory therapy...
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
For the treatment of pancreatic cancer, EryTech are now looking to develop 'tumour starvation' treatments for acute leukaemia and have enrolled their...
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The primary endpoint of the trial being the percentage of patients who achieved a sustained virologic response 12 weeks after treatment (SVR12)...
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The drug is the first treatment to target hypophosphatasia, a condition affecting the development of bone, and could allow children to lead a normal life...
